Carrera Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.2M Buy
2,764
+1,757
+174% +$2.07M 0.45% 49
2026
Q2
$1.21M Buy
1,007
+171
+20% +$175K 0.18% 89
2026
Q1
$769K Sell
836
-37
-4% -$37.5K 0.12% 95
2025
Q4
$939K Buy
873
+144
+20% +$138K 0.16% 76
2025
Q3
$557K Buy
729
+53
+8% +$39.4K 0.1% 88
2025
Q2
$527K Buy
676
+43
+7% +$33.4K 0.11% 93
2025
Q1
$523K Buy
633
+257
+68% +$214K 0.12% 105
2024
Q4
$290K Buy
376
+101
+37% +$83.6K 0.07% 118
2024
Q3
$244K Buy
+275
New +$247K 0.06% 102

Other funds holding LLY

Carrera Capital Advisors's LLY Position: Q3 2026 in Review

Carrera Capital Advisors increased its Eli Lilly (LLY) stake by 174% in Q3 2026, buying an estimated $2.07M and bringing the position to 2,764 shares worth $3.2M. The position accounts for 0.45% of the portfolio, ranked #49.

Carrera Capital Advisors first reported a position in LLY in Q3 2024 and has held it in 9 quarters since. 4,625 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Carrera Capital Advisors held 2,764 shares of Eli Lilly worth $3.2M as of Q3 2026.
  • Carrera Capital Advisors bought 1,757 Eli Lilly shares in Q3 2026, an estimated $2.07M.
  • Eli Lilly made up 0.45% of Carrera Capital Advisors's portfolio in Q3 2026, its #49 holding.
  • Carrera Capital Advisors first reported a position in Eli Lilly in Q3 2024 and has held it in 9 quarters since.
  • 4,625 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Carrera Capital Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.